Top

Published in:

01-06-2017 | Original Article

Hepatic FDG uptake is associated with future cardiovascular events in asymptomatic individuals with non-alcoholic fatty liver disease

Authors: Seung Hwan Moon, MD, PhD, Sun-pyo Hong, MD, Young Seok Cho, MD, PhD, Tae Soo Noh, BA, Joon Young Choi, MD, PhD, Byung-Tae Kim, MD, PhD, Kyung-Han Lee, MD, PhD

Published in: Journal of Nuclear Cardiology | Issue 3/2017

Abstract

Background

Hepatic F-18 fluoro-2-deoxyglucose (FDG) uptake is associated with non-alcoholic fatty liver disease (NAFLD) which is an independent risk factor for cardiovascular disease. However, the value of hepatic FDG uptake for predicting future cardiovascular events has not been explored.

Methods and Results

Study participants were 815 consecutive asymptomatic participants who underwent a health screening program that included FDG positron emission tomography/computed tomography (PET/CT), abdominal ultrasonography, and carotid intima-media thickness (CIMT) measurements (age 51.8 ± 6.0 year; males 93.9%). We measured hepatic FDG uptake and assessed the prognostic significance of this parameter with other cardiovascular risk factors including Framingham risk score and CIMT. Multivariate Cox proportional hazards analyses including all study participants revealed that NAFLD with high-hepatic FDG uptake was the only independent predictor for future cardiovascular events [hazard ratio (HR) 4.23; 95% CI 1.05-17.04; P = .043). Subgroup analysis conducted in the NAFLD group showed that high-hepatic FDG uptake was a significant independent predictor of cardiovascular events (HR 9.29; 95% CI 1.05-81.04; P = .045).

Conclusions

This exploratory study suggests that high-hepatic FDG uptake may be a useful prognostic factor for cardiovascular events in individuals with NAFLD.

Available only for authorised users

Lu H, Zeng L, Liang B, Shu X, Xie D. High prevalence of coronary heart disease in type 2 diabetic patients with non-alcoholic fatty liver disease. Arch Med Res 2009;40:571-5.CrossRefPubMed

Treeprasertsuk S, Lopez-Jimenez F, Lindor KD. Nonalcoholic fatty liver disease and the coronary artery disease. Dig Dis Sci 2011;56:35-45.CrossRefPubMed

Dunn W, Xu R, Wingard DL, Rogers C, Angulo P, Younossi ZM, et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 2008;103:2263-71.CrossRefPubMedPubMedCentral

Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008;49:608-12.CrossRefPubMed

Brea A, Puzo J. Non-alcoholic fatty liver disease and cardiovascular risk. Int J Cardiol 2013;167:1109-17.CrossRefPubMed

Targher G, Bertolini L, Padovani R, Rodella S, Arcaro G, Day C. Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol 2007;46:1126-32.CrossRefPubMed

Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-9.CrossRefPubMed

Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009;7:234-8.CrossRefPubMed

Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-73.CrossRefPubMed

10.

Soderberg C, Stal P, Askling J, Glaumann H, Lindberg G, Marmur J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010;51:595-602.CrossRefPubMed

11.

Kotronen A, Yki-Jarvinen H. Fatty liver: A novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008;28:27-38.CrossRefPubMed

12.

de Alwis NM, Day CP. Non-alcoholic fatty liver disease: The mist gradually clears. J Hepatol 2008;48:S104-12.CrossRefPubMed

13.

Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: Causal effect or epiphenomenon? Diabetologia 2008;51:1947-53.CrossRefPubMed

14.

Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007;132:2169-80.CrossRefPubMed

15.

Stefan N, Kantartzis K, Haring HU. Causes and metabolic consequences of Fatty liver. Endocr Rev 2008;29:939-60.CrossRefPubMed

16.

Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 2002;105:2708-11.CrossRefPubMed

17.

Keramida G, Potts J, Bush J, Verma S, Dizdarevic S, Peters AM. Accumulation of (18)F-FDG in the liver in hepatic steatosis. AJR Am J Roentgenol 2014;203:643-8.CrossRefPubMed

18.

Bural GG, Torigian DA, Burke A, Houseni M, Alkhawaldeh K, Cucchiara A, et al. Quantitative assessment of the hepatic metabolic volume product in patients with diffuse hepatic steatosis and normal controls through use of FDG-PET and MR imaging: A novel concept. Mol Imaging Biol 2010;12:233-9.CrossRefPubMed

19.

Keramida G, Potts J, Bush J, Dizdarevic S, Peters AM. Hepatic steatosis is associated with increased hepatic FDG uptake. Eur J Radiol 2014;83:751-5.CrossRefPubMed

20.

Hong SP, Noh TS, Moon SH, Cho YS, Lee EJ, Choi JY, et al. Hepatic glucose uptake is increased in association with elevated serum gamma-glutamyl transpeptidase and triglyceride. Dig Dis Sci 2014;59:607-13.CrossRefPubMed

21.

Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med 2006;47:885-95.PubMed

22.

Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 1986;292:13-5.CrossRef

23.

Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-analysis. Hepatology 2011;54:1082-90.CrossRefPubMedPubMedCentral

24.

Figueroa AL, Abdelbaky A, Truong QA, Corsini E, MacNabb MH, Lavender ZR, et al. Measurement of arterial activity on routine FDG PET/CT images improves prediction of risk of future CV events. JACC Cardiovasc Imaging 2013;6:1250-9.CrossRefPubMed

25.

Abele JT, Fung CI. Effect of hepatic steatosis on liver FDG uptake measured in mean standard uptake values. Radiology 2010;254:917-24.CrossRefPubMed

26.

Borra R, Lautamaki R, Parkkola R, Komu M, Sijens PE, Hallsten K, et al. Inverse association between liver fat content and hepatic glucose uptake in patients with type 2 diabetes mellitus. Metabolism 2008;57:1445-51.CrossRefPubMed

27.

Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology 2005;129:113-21.CrossRefPubMed

28.

Tilg H, Moschen AR. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab 2008;19:371-9.CrossRefPubMed

29.

Targher G, Chonchol M, Miele L, Zoppini G, Pichiri I, Muggeo M. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin Thromb Hemost 2009;35:277-87.CrossRefPubMed

30.

Targher G, Bertolini L, Rodella S, Lippi G, Franchini M, Zoppini G, et al. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity 2008;16:1394-9.CrossRefPubMed

31.

Schoder H, Gonen M. Screening for cancer with PET and PET/CT: Potential and limitations. J Nucl Med 2007;48:4S-18S.CrossRefPubMed

32.

Boyce CJ, Pickhardt PJ, Kim DH, Taylor AJ, Winter TC, Bruce RJ, et al. Hepatic steatosis (fatty liver disease) in asymptomatic adults identified by unenhanced low-dose CT. AJR Am J Roentgenol 2010;194:623-8.CrossRefPubMed

33.

Ma X, Holalkere NS, Kambadakone RA, Mino-Kenudson M, Hahn PF, Sahani DV. Imaging-based quantification of hepatic fat: Methods and clinical applications. Radiographics 2009;29:1253-77.CrossRefPubMed

Title: Hepatic FDG uptake is associated with future cardiovascular events in asymptomatic individuals with non-alcoholic fatty liver disease
Authors: Seung Hwan Moon, MD, PhD
Sun-pyo Hong, MD
Young Seok Cho, MD, PhD
Tae Soo Noh, BA
Joon Young Choi, MD, PhD
Byung-Tae Kim, MD, PhD
Kyung-Han Lee, MD, PhD
Publication date: 01-06-2017
Publisher: Springer US
Published in: Journal of Nuclear Cardiology / Issue 3/2017
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-015-0297-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Hepatic FDG uptake is associated with future cardiovascular events in asymptomatic individuals with non-alcoholic fatty liver disease

Abstract

Background

Methods and Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods and Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2017

Comparison of ESC and ACC/AHA guidelines for myocardial revascularization: are the differences clinically relevant? The European perspective

The effect of coronary revascularization on regional myocardial blood flow as assessed by stress positron emission tomography

Coronary artery calcium scanning in symptomatic patients: Ready for use as a gatekeeper for further testing?

Utility of multimodality imaging in myopericarditis with aortitis

Guiding coronary revascularization using PET stress myocardial perfusion imaging: The proof is in the pudding

Multicenter evaluation of stress-first myocardial perfusion image triage by nuclear technologists and automated quantification